BCL2 and benign prostatic hyperplasia: In BPH-1 cells, SIN therapy inhibited the protein expression of Bcl-2 significantly (p < 0.001) (Figure 1F) and enhanced the protein expression of Bax in BPH-1 cells significantly (p < 0.05) (Figure 1G).